Le Lézard
Classified in: Health
Subjects: PDT, FDA

Padagis Announces The FDA Approval And Launch Of An AB Rated Generic Version Of Doxil® (Doxorubicin Liposome Injection)


ALLEGAN, Mich., Oct. 21, 2021 /PRNewswire/ -- Padagis today announced the FDA approval and launch of an AB-rated generic version of Doxil® (Doxorubicin Liposome Injection) through its partnership with Ayana Pharma Ltd.

Doxil® Liposome Injection is an anthracycline topoisomerase inhibitor indicated for Ovarian Cancer, AIDS-related Kaposi's Sarcoma and Multiple Myeloma. Annual market sales for Doxil® Liposome Injection for the 12 months ending August 2021 were approximately $98 million as measured by IQVIA.

Padagis Executive Vice President and Chief Growth Officer, Colter VanStedum, stated "This launch is the culmination of several years of working with the Ayana team to bring this highly complex product to market. By also highlighting our business development capabilities in leveraging our regulatory & technical expertise and commercial platform, we are able to bring this unique product to our customers and patients in need of a high-quality generic alternative."

About Padagis

Padagis is dedicated to improving the well-being of as many patients and consumers as possible by developing, manufacturing and distributing high quality, affordable specialized healthcare products.  The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide. Visit Padagis online at (http://www.padagis.com).

SOURCE Padagis


These press releases may also interest you

at 06:00
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its...

at 06:00
Organ donation and transplantation: CLOSE TO 80% OF QUEBECERS WANT SPECIFIC AND COMPREHENSIVE LEGISLATION
According to a Léger survey conducted for Transplant Québec, more than three in four people favour the adoption, by Québec, of specific and comprehensive legislation governing organ donation and transplantation. At a time when the National Assembly...

at 05:30
Star Gala inspires $2.3 million in giving to support Children's Minnesota neuroscience program and first-of-its kind pediatric surgery suite
Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities...

at 04:04
European Wellness Leads Pioneering Down Syndrome Research at Heidelberg University
The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...

at 03:30
Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

at 03:00
Todd Britten, DMD: Leading the Way in Periodontal Excellence
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...

More news about Health...


News published on and distributed by: